|
The Role of Neuropsychological Medications in Inflammatory Bowel Disease
|
Parvaneh Rahimi-Moghaddam   , Afrooz Mohammad Gholi Beyki |
|
|
|
Abstract: (286 Views) |
Introduction: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract with significant physical and psychological burdens. While the etiology of IBD remains elusive, emerging evidence suggests a complex interplay between immune dysregulation, gut microbiota alterations, and psychosocial factors, including stress and depression. The gut-brain axis is a bidirectional communication network between the gastrointestinal system and the central nervous system. The gut microbiota produce neurotransmitters and other bioactive compounds that can affect neural signaling. Additionally, the gut is lined with a complex network of neurons known as the enteric nervous system (ENS). The ENS communicates bi-directionally with the central nervous system. Treatment of IBD depends on the form and level of severity. Common treatment involves an anti-inflammatory drug, such as mesalazine, and an immunosuppressant, such as prednisone. Neuropsychological medications, such as antidepressants and anxiolytics, have been commonly prescribed to manage the psychological symptoms in IBD patients. Recent studies have revealed that these medications might possess additional therapeutic properties beyond their primary use in psychiatric disorders. Recent Preclinical studies utilizing animal models of IBD, have demonstrated that antidepressants exert anti-inflammatory effects. Furthermore, these medications have shown potential in restoring intestinal barrier integrity by promoting mucosal healing and reducing epithelial permeability. Moreover, emerging evidence suggests potential beneficial effects of antidepressants on gut microbiota composition and gut-brain signaling. In conclusion, while antidepressants are primarily prescribed for managing depressive symptoms in IBD patients, their potential immunomodulatory, barrier-protective, and psychotropic properties make them an intriguing adjunctive therapy in the management of IBD. A better understanding of the role of antidepressants in IBD could pave the way for drug repositioning and personalized therapeutic strategies that target both physical and psychological aspects of this debilitating disease.
|
|
| Keywords: inflammatory bowel disease, gut microbiota, antidepressants, enteric nervous system |
|
|
Full-Text [PDF 250 kb]
(36 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2024/01/13 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
